Castration-resistant (CR) prostate cancer (PCa) treatment options are limited. A substantial
sub-population of CR PCa tumors can synthesize androgens for intracrine androgen …

The treatment of castration-resistant (CR) prostate cancer (PCa) is limited. A sub-population
of CR PCa tumors can synthesize androgens for intracrine androgen receptor (AR) …

Background: One of the growth mechanisms of castration-resistant prostate cancer (CRPC)
is de novo androgen synthesis from intracellular cholesterol, and statins may be able to …

Background One of the growth mechanisms of castration‐resistant prostate cancer (CRPC)
is de novo androgen synthesis from intracellular cholesterol, and statins may be able to …

Background In castration-resistant prostate cancer (CRPC), recent evidence has
demonstrated the persistence of the intratumoral androgens. The multi-step androgen …

Androgen receptor (AR) signaling inhibitors (ARSIs) bicalutamide (Bic) and enzalutamide
(Enza) are used in the treatment of castration resistant prostate cancer (CRPC). Prostate …

Objective Even though the exact mechanism is largely unknown until now, statins are
supposed to improve survival outcomes in various malignancies. For prostate cancer …

Androgen deprivation therapy (ADT) continues to be the mainstay therapy for advance-stage
prostate cancer. Although malignant cells respond to ADT initially, subsequently colonize …

Background Although statin use has been associated with favorable effects in various solid
malignancies, no conclusive evidence is available at present. Statins are safe and …

While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all
men with advanced prostate cancer will eventually progress to the more resistant, and …